PMID- 32806874
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20211113
IS  - 1598-9100 (Print)
IS  - 2288-1956 (Electronic)
IS  - 1598-9100 (Linking)
VI  - 19
IP  - 4
DP  - 2021 Oct
TI  - Is there a correlation between infliximab trough levels and the development of 
      adverse events in patients with inflammatory bowel disease?
PG  - 461-467
LID - 10.5217/ir.2020.00042 [doi]
AB  - BACKGROUND/AIMS: The measurement of infliximab trough levels (IFX-TLs) in 
      patients with inflammatory bowel disease (IBD) is performed to optimize 
      treatment. However, the association between the development of adverse events 
      (AEs) and IFX-TLs has not been sufficiently studied thus far. To investigate the 
      possible association of IFX-TLs with AEs in Greek patients with IBD receiving 
      maintenance treatment with IFX. METHODS: A retrospective analysis of the registry 
      data of the Gastroenterology Department of the University Hospital of Heraklion, 
      from IBD patients with at least one available IFX-TL measurement during the years 
      2016 to 2017 was conducted. AEs reported 4 months before and 4 months after the 
      measured IFX-TLs were recorded. The IFX-TLs of patients with or without AEs were 
      compared. RESULTS: Of a total of 83 IBD patients (61 Crohn's disease [73%]; 52 
      men [63%]; mean age +/- standard deviation, 43.3 +/- 16.0 years), 147 measurements of 
      IFX-TLs were available (median 4.69 mug/ mL [1.32-9.16]), and 99 AEs (67.3%, 14 
      severe) were registered. The median IFX-TL of patients with AEs was 5.79 mug/mL 
      (1.36- 10.25), higher than the median IFX-TL of patients without AEs (3.40 mug/mL 
      [1.30-5.92]), but the difference was not significant (P= 0.97). The presence of 
      infections or dermatologic reactions was not correlated with IFX-TLs. There was 
      no difference in the prevalence of the total AEs (66.7% vs. 73.3%, P= 0.77) or in 
      the analysis of AEs by group between patients with IFX-TLs >/= 15 mug/ mL and 
      patients with IFX-TLs < 15 mug/mL. CONCLUSIONS: IFX-TLs are not significantly 
      associated with the development of AEs in IBD patients receiving maintenance 
      treatment with IFX.
FAU - Theodoraki, Eirini
AU  - Theodoraki E
AD  - Department of Gastroenterology, University Hospital of Heraklion, Medical School 
      University of Crete, Heraklion, Greece.
FAU - Orfanoudaki, Eleni
AU  - Orfanoudaki E
AD  - Department of Gastroenterology, University Hospital of Heraklion, Medical School 
      University of Crete, Heraklion, Greece.
FAU - Foteinogiannopoulou, Kalliopi
AU  - Foteinogiannopoulou K
AD  - Department of Gastroenterology, University Hospital of Heraklion, Medical School 
      University of Crete, Heraklion, Greece.
FAU - Legaki, Evangelia
AU  - Legaki E
AD  - Department of Basic Medical Sciences, Laboratory of Biology, National and 
      Kapodistrian University of Athens Medical School, Athens, Greece.
FAU - Gazouli, Maria
AU  - Gazouli M
AD  - Department of Basic Medical Sciences, Laboratory of Biology, National and 
      Kapodistrian University of Athens Medical School, Athens, Greece.
FAU - Koutroubakis, Ioannis E
AU  - Koutroubakis IE
AD  - Department of Gastroenterology, University Hospital of Heraklion, Medical School 
      University of Crete, Heraklion, Greece.
LA  - eng
PT  - Journal Article
DEP - 20200818
PL  - Korea (South)
TA  - Intest Res
JT  - Intestinal research
JID - 101572802
PMC - PMC8566825
OTO - NOTNLM
OT  - Adverse drug events
OT  - Colitis, ulcerative
OT  - Crohn disease
OT  - Infections
OT  - Infliximab
COIS- Conflict of Interest No potential conflict of interest relevant to this article 
      was reported.
EDAT- 2020/08/19 06:00
MHDA- 2020/08/19 06:01
PMCR- 2021/10/01
CRDT- 2020/08/19 06:00
PHST- 2020/05/02 00:00 [received]
PHST- 2020/05/25 00:00 [accepted]
PHST- 2020/08/19 06:00 [pubmed]
PHST- 2020/08/19 06:01 [medline]
PHST- 2020/08/19 06:00 [entrez]
PHST- 2021/10/01 00:00 [pmc-release]
AID - ir.2020.00042 [pii]
AID - ir-2020-00042 [pii]
AID - 10.5217/ir.2020.00042 [doi]
PST - ppublish
SO  - Intest Res. 2021 Oct;19(4):461-467. doi: 10.5217/ir.2020.00042. Epub 2020 Aug 18.